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Abstract
Background: C5L2 has been demonstrated to be a functional receptor of acylation-stimulating protein (ASP), which is a
stimulator of triglyceride synthesis or glucose transport. However, little is known about the variations in the coding region
of the C5L2 gene and their association with coronary artery disease (CAD).
Methodology/Principal Findings: We identified a novel single nucleotide polymorphism (SNP), 698C.T (P233L), in exon 2
using a polymerase chain reaction direct-sequencing method. This nucleotide change causes the amino-acid order from
proline to leucine at codon 233. We examined the role of this SNP for CAD using two independent case–control studies: one
was in the Han population (492 CAD patients and 577 control subjects) and the other was in the Uygur population (319 CAD
patients and 554 control subjects). Heterozygote carriers of the 698CT genotype were more frequent among CAD patients
than among controls not only in the Han population (7.3% versus 1.7%) but also in the Uygur population (4.7% versus 1.6%).
The odds ratio (OR) for carriers of the 698CT genotype for CAD was 4.484 (95% confidence interval (CI): 2.197–9.174) in the
Han group and 2.989 (95% CI: 1.292–6.909) in the Uygur population. After adjustment of confounding factors such as sex,
age, smoking, alcohol consumption, hypertension, diabetes, as well as serum levels of triglyceride, total cholesterol, high-
density lipoprotein, the difference remained significant in the Han group (P,0.001, OR=6.604, 95% CI: 2.776–15.711) and in
the Uygur group (P=0.047, OR=2.602, 95% CI: 1.015–6.671).
Conclusion/Significance: The 698CT genotype of C5L2 may be a genetic maker of CAD in the Han and Uygur population in
western China.
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Introduction
The etiology and pathogenesis of coronary artery disease (CAD)
are likely to comprise a multifactorial disorder resulting from
inheritance of several susceptibility genes, as well as multiple envi-
ronmental determinants [1,2]. Disorders of lipoprotein metabolism
such as elevated levels of triglyceride (TG) as well as increased
fasting blood glucose are considered to be important risk factors in
the pathogenesis of atherosclerosis and CAD [3–5]. Therefore,
many genes involved in the metabolism of glucose and lipid have
been considered to be the candidate gene of CAD. These include
the genes for: ATP-binding cassette A (ABCA1) [6], peroxisome
proliferator activated receptor-gamma (PPARc) [7], proprotein
convertase subtilisin/kexin type 5 [8], and apolipoprotein E [9].
C5L2, a G protein-coupled receptor (GPCR), was demonstrated
to be a functional receptor of acylation-stimulating protein (ASP)
[10–12]. ASP is also known as C3a des-Arg, a stimulator of TG
synthesis [13–16] or glucose transport [17,18]. One study [19] dem-
onstrated that ASP initiates a cascade of events that includes phos-
phorylation, b-arrestin translocation, and receptor internalization
by binding to C5L2. Activation of C5L2 initiates a signaling
pathway which includes activation and translocation of protein
kinase C as well as translocation of the glucose transporter [20–22].
Activation of this pathway results in increased transport of glucose
and esterification of fatty acids, leading to a net accumulation of TG
stores in adipose tissue. Accordingly, the activity of C5L2 may
influence the body’s susceptibility to CAD.
Recently, Marcil et al. [23] identified a novel C5L2 variant
(S323I) in a French–Canadian family with familial combined
hyperlipidemia. This single nucleotide polymorphism (SNP) was
associated with increased plasma TG, cholesterol, low-density
lipoprotein-cholesterol (LDL-C), apolipoprotein B and ASP.
However, our research team could not identify this SNP in the
Han and Uygur population in China. According to the Internet
website of the National Centre of Biotechnology Information
(NCBI; (www.ncbi.nlm.nih.gov/SNP)), the genetic variants of the
human C5L2 gene include 52 SNPs. Of these SNPs, only 4 SNPs
(rs112564060, rs78669180, rs117238101, and rs112290646) yield
a change in amino acids. To date, no more SNPs have been
identified in the coding region of the C5L2 gene.
Accordingly, we screened for possible mutations and polymor-
phisms of the C5L2 gene and assessed the association between the
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sought to replicate any associations detected in the Uygur
population between the genotypes of this gene and CAD.
Methods
Ethical approval of the study protocol
This study was approved by the Ethics Committee of the First
Affiliated Hospital of Xinjiang Medical University (Xinjiang,
China). It was conducted according to the standards of the
Declaration of Helsinki. Written informed consent was obtained
from all participants.
Subjects
Two patient populations (Han and Uygur) with CAD were
studied independently. Four hundred and ninety-two Han patients
and 319 Uygur patients diagnosed with CAD at the First Affiliated
Hospital of Xinjiang Medical University from January 2006 to
December 2009 were recruited. They acted as the first CAD
group and second CAD group, respectively. The detailed
diagnostic and selection criteria have been previously described
[24–25]. Briefly, CAD was defined as the presence of at least one
significant coronary artery stenosis of .50% luminal diameter on
coronary angiography. Patients were excluded if they had
congenital hypercoagulable status with proven disease-limiting life
expectancy or had abused cocaine.
For each CAD patient group, we selected healthy participants
matched for ethnicity, sex, and age as the controls. Control
subjects were selected from the Cardiovascular Risk Survey (CRS)
[26–27]. This consists of 14,618 subjects and is a multiple-ethnic,
community-based, cross-sectional study designed to investigate the
prevalence, incidence, and risk factors for cardiovascular diseases
in the Han, Uygur, and Kazakh population in Xinjiang (west
China) between June 2007 and March 2010. These individuals did
not have: a history of CAD; electrocardiographic signs of CAD;
regional wall motion abnormalities; relevant valvular abnormal-
ities in echocardiograms [28]. Diabetes, hypertension, hyperlipi-
demia, smoking, and alcohol consumption were defined as
previously described [24,25,29].
Biochemical analysis
Serum concentrations of total cholesterol (TC), TG, glucose,
high-density lipoprotein cholesterol (HDL-C), LDL-C, blood urea
nitrogen (BUN), creatinine (Cr) and uric acid were measured using
standard methods in the Central Laboratory of First Affiliated
Hospital of Xinjiang Medical University as described previously
[24,25,29].
Primer design and C5L2 gene sequencing
Sequence information for use as a reference template was
obtained from the Ensembl Genome Browser (Human, number
ENSG00000134830). Sequencing primers were designed using
Figure 1. Restriction fragment length polymorphism analyses for determination of genotype (A). The CT genotype shows three bands
of 286 bp, 153 bp, and 133 bp (1 and 2); the CC genotype shows two bands of 153 bp and 133 bp (3, 4 and 5). Nucleotide sequences around the
698C.T polymorphism (a, CT genotype; b, CC genotype) (B).
doi:10.1371/journal.pone.0020984.g001
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CACTTCTA ACAACA39 and the antisense primer was 59GTT-
GAATGAAGGAAGGAATAA39. Extraction of genomic DNA
from peripheral blood samples has been described previously
[24,25]. The polymerase chain reaction (PCR) was undertaken with
50 ng of genomic DNA in a 20 mL reaction containing 10 mLo f
Power Mix (Beijing Biotech, Beijing, China), 9.5 mL of distilled
water, and 0.2 mM of each forward and reverse primer. A
GeneAmp 9700 thermal cycler (Applied Biosystems, Foster City,
CA, USA) was used for PCR amplification. An initial denaturation
step at 95uC for 5 min, 40 cycles of 95uC for 30 s, 56uC for 30 s,
and 72uC for 1 min was followed by a final extension step of 72uC
for 10 min. A 1615-base pair (bp) product was amplified was
purified using ExoSAP-IT (Amersham Biosciences) according to
manufacturer’s instructions before it was used as a template for
sequencing. Sequencing reactions were undertaken by BGI-Beijing
(Beijing, China; http://www.genomics.cn).
Genotyping of novel SNPs
Complete sequencing of the C5L2 region that included a
portion of the upstream region, 1 intron, and the exon with the
complete coding region was initially conducted on 48 subjects with
CAD. A novel SNP (698C.T) causes the change in amino acids
from proline to leucine at codon 233. Genotyping for the 698C.T
C5L2 gene variant in the present case–control study was done by
PCR amplification of 286 bp in exon 2 followed by restriction
digestion with BamH I (Fermentas, Beijing, China). The sense
primer was 59ACT ACG GCG GCT CCT CCA 39 and the
antisense primer was 59TGT GAG CGA GGG CAA GGC 39.
The annealing temperature was 63uC. The PCR product (15 mL)
was incubated overnight with BamH I (5 U) in a total volume of
25 mLa t3 7 uC, and the resulting fragments separated on 3.0%
agarose gel. Absence of the 698C.T variant created a BamH I site
producing two fragments of 133 bp and 153 bp (Figure 1A). To
confirm the results, we used sequenced genomic DNAs as positive
controls in our assays.
Statistical analyses
Analyses were carried out using SPSS version 17.0 (SPSS,
Chicago, IL, USA). The Hardy–Weinberg equilibrium was
assessed by chi-square analyses. Measurement data are shown as
means 6SD, and the differences between CAD patients and
control subjects were assessed by independent-sample t-test.
Fasting TGs were log-transformed using natural logarithms for
analyses and presented as geometric means and the inter-quartile
range (25th–75th quartile). Differences in enumeration data
between CAD patients and control subjects were analyzed using
the chi-square test, as were differences in distributions of genotypes
and alleles between CAD patients and control subjects. Logistic
regression analyses were used to assess the contribution of the
major risk factors.
Results
Participant characteristics
Table 1 shows the clinical characteristics of CAD patients
(n=492) and control (n=577) Han and Uygur subjects. In Han
subjects, the following variables were significantly different
between the two groups: hypertension; diabetes; smoking; and
the serum concentration of HDL-C, LDL-C, creatinine and BUN
(all P,0.05). There was no significant difference in the following
variables between CAD patients and control subjects: serum
concentration of uric acid and TG; the body mass index (BMI);
alcohol consumption; age; and sex (all P.0.05). In Uygur subjects,
the following variables were also significantly different between
these two groups: hypertension; diabetes; smoking; alcohol
consumption and the serum concentration of HDL-C, TG and
uric acid (all P,0.05). There was no significant difference in the
Table 1. Characteristics of the participant.
Han Uygur
Control (n=577) CAD (n=492) x
2 or tP value Control (n=554) CAD (n=319) x
2 or tP value
Age, mean (SD) 57.70 (11.75) 58.45 (10.29) 1.591 0.112 49.89 (17.78) 49.69 (14.47) 2.181 0.856
Sex, female (%) 129 (0.224) 104 (0.211) 1.015 0.314 90(19.12) 62(15.38) 1.43 0.138
Hypertension, n (%) 309 (53.5) 315 (64.0) 10.979 0.001 141(26.26) 116(38.67) 13.93 ,0.001
Diabetes, n (%) 167 (28.9) 241(49.0) 44.876 ,0.001 63(11.87) 83(27.67) 32.91 ,0.001
Smoking, n (%) 225 (39.0) 291 (59.1) 41.884 ,0.001 210(38.11) 168(53.16) 17.96 ,0.001
Drinking, n (%) 184 (31.9) 184 (37.4) 3.394 0.065 158(28.52) 116(36.36) 5.78 0.01
BMI, mean (SD) 25.67 (3.30) 184 (37.4) 1.563 0.118 26.37(4.04) 26.84(4.86) 21.48 0.786
SBP, mean (SD) 133.08(18.85) 141.69(31.39) 24.602 ,0.001 141.26(29.49) 123.41(17.27) 4.777 ,0.001
DBP, mean (SD) 83.74 (14.12) 86.26 (17.92) 22.291 0.022 86.73(17.75) 76.26(10.54) 4.65 ,0.001
Glucose, mean (SD) 4.88 (0.97) 6.22 (2.34) 212.378 ,0.001 5.51(1.82) 5.93(2.40) 22.72 ,0.001
TG, mean (SD) 1.85 (1.66) 2.03 (1.82) 21.600 0.110 1.92(1.82) 1.84(0.90) 0.727 ,0.001
TC, mean (SD) 4.49 (1.03) 4.17 (1.03) 4.805 ,0.001 4.53(1.23) 4.21(1.04) 3.50 0.235
HDL-C, mean (SD) 1.33 (0.40) 1.13 (0.32) 8.406 ,0.001 1.17(0.63) 1.00(0.28) 4.14 ,0.001
LDL-C, mean (SD) 2.93 (1.02) 2.52 (0.85) 6.819 ,0.001 2.68(0.94) 2.62(0.93) 0.874 0.869
UA, mean (SD) 330.64(91.68) 331.47(85.94) 2.149 0.881 304.75(87.04) 321.99(87.91) 22.62 0.009
Cr, mean (SD) 74.25 (18.37) 78.53 (26.50) 23.039 0.002 78.41(22.81) 78.70(21.81) 21.71 0.120
BUN, mean (SD) 4.99(1.50) 5.29(1.72) 23.010 0.003 5.16(1.74) 5.23(1.79) 2.521 0.602
doi:10.1371/journal.pone.0020984.t001
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the serum concentration of LDL-C, creatinine and BUN; the
BMI; age and sex (all P.0.05).
Distribution of the 698C.T in CAD patients and controls
The genotype distribution of this SNP did not show a significant
difference from the Hardy–Weinberg equilibrium values in both
ethnicities (P.0.05 in CAD group and control group). The
frequency of the heterozygote carriers of the 698-CT genotype of
C5L2 was significantly higher in CAD patients than in Han control
subjects (7.3% versus 1.7%; P,0.001) and Uygur subjects (4.7%
versus 1.6%; P=0.008) (Table 2). The frequency of the T allele in
CAD patients was higher than that in Han control subjects (4.0%
versus 1.0%, P,0.001) and in Uygur subjects (2.0% versus 1.0%;
P=0.008) (Table 2). The odds ratio (OR) for carriers of the
698CT genotype for CAD was 4.484 [95% confidence interval
(CI): 2.197–9.174] in Han subjects and 2.989 [95% CI: 1.292–
6.909] in the Uygur population. After adjustment of confounders
such as hypertension, diabetes, smoking, systolic blood pressure,
diastolic blood pressure, and the serum concentration of HDL-C,
LDL-C, creatinine and BUN, the difference remained significant
in Han subjects (P,0.001, OR=6.604, 95%CI: 2.776–15.711)
and in the Uygur population (P=0.047, OR=2.602, 95% CI:
1.015–6.671) (Table 3).
Relationship between the C5L2 genetic polymorphism
and LDL-C levels
To investigate further the functional role of the C5L2
polymorphism, we compared the concentrations of LDL-C
between carriers with the CC genotype and carriers with the
CT genotype of the C5L2 gene. LDL-C concentrations were
significantly higher in samples from control subjects with the C5L2
CT genotype than in participants with the CC genotype in Han
subjects (2.74 mmol/L versus 2.41 mmol/L; Figure 2A) and in
Uygur subjects (2.77 mmol/L versus 2.36 mmol/L; Figure 2B).
This results indicated that the T allelle is associated with higher
LDL levels than the C allele in the control population. However
the correlation between the LDL level and the T-allele is low both
in CAD paitents (r=0.11, P=0.784) and in the control subjects
(r=0.19, P=0.501).
Discussion
We identified a novel SNP (698C.T) and found that the minor
allele of 698C.T (SNP in C5L2) had a higher frequency in CAD
patients than in controls in the Han and Uygur population of
Xinjiang.
In the present study, we only selected the Han and the Uygur
population acting as the participants. According to a national
enquiry, 13 ethnics have been confirmed as original ethnic in
Xinjiang, including the Uygur, Han, Kazak, Hui, Mongol, Kirgiz,
Xibe, Manchu, Ozbek, Russian, Daur and Tatar people. Among
them, the Uygur people account for 46% and the Han account for
40%. The fact that there were many ethnics in Xinjiang may be a
confounding factor of the present study. So, the genetic back-
grounds of these different ethnics may be helpful to understand this
issue. However, Up to date, there are no completed data of these 13
ethnics’ genetic backgrounds. Although there are many ethnic
groups living in this area, miscegenation is very rare. When we
selected the participants for the present study, we excluded those
who had a history of miscegenation to ensure the homozygous
nature of the samples.
Factors such as diabetes, hypertension, and hyperlipidemia have
been reported to influence the pathogenesis of CAD. Like
hyperlipemia and diabetes, CAD is thought to be a multifactorial
disease. Hence, much attention has been focused on the
association of gene polymorphisms with CAD.
Table 2. Distribution of genotypes and alleles of C5L2 gene.
Group n Genotype ( n, %) P Allele (Frequency) P
CC CT C T
Han population Control 577 567(98.3) 10(1.7) ,0.001 0.99 0.01 ,0.001
CAD 492 456(92.7) 36(7.3) 0.96 0.04
Uygur population Control 554 545(98.4) 9 (1.6) 0.008 0.99 0.01 0.008
CAD 319 304(95.3) 15(4.7) 0.98 0.02
doi:10.1371/journal.pone.0020984.t002
Table 3. Results of Logistic analysis.
Uygur Han
B S.E. Wald P OR 95% C.I. B S.E. Wald P OR 95% C.I.
698C.T 0.956 0.48 3.96 0.047 2.602 1.015,6.671 1.888 0.442 18.225 ,0.001 6.604 2.776,15.711
Smoking 0.424 0.167 6.435 0.011 1.527 1.101,2.119 0.748 0.149 25.323 ,0.001 2.112 1.579,2.827
Diabetes 0.944 0.205 21.221 ,0.001 2.57 1.720,3.839 0.838 0.151 30.626 ,0.001 2.311 1.718,3.110
HDL-C 21.034 0.284 13.244 ,0.001 0.356 0.204,0.621 21.571 0.216 52.864 ,0.001 0.208 0.136,0.317
Constant 3.168 0.687 21.285 ,0.001 23.771 3.168 0.687 21.285 ,0.001 23.771
doi:10.1371/journal.pone.0020984.t003
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genes that may be involved in CAD is based on a candidate gene
approach. A few studies into the genetic polymorphisms of the
C5L2 receptor located on chromosome 19q13 (the region
identified to be associated with familial combined hyperlipidemia
and the pre-diabetic state by genome-wide scan studies) have been
completed [30,31]. Familial combined hyperlipidemia is consid-
ered to be the most frequent lipoprotein disorder in premature
CAD [32]. Therefore, the C5L2 gene is thought to be a candidate
gene for CAD.
We genotyped the 698C.T polymorphism and assessed the
association between C5L2 and CAD. The frequency of the CT
genotype was significantly higher in CAD patients than in
control subjects not only in the Han group but also in the Uygur
group. This indicated that the risk of CAD was increased in
subjects with the T allele. Logistic regression analyses suggested
that, after adjustment for other cardiovascular risk factors, the
CT genotype remained significant between CAD patients and
control subjects.
Michel et al. [23] identified a novel variant in the C5L2 gene.
This was a non-synonymous mutation; it was an AGCRATC
variant resulting in a S323-to-I substitution which was associated
with familial combined hyperlipidemia in a French–Canadian
family. Gain-of-function studies in human C5L2 stably trans-
fected HEK-293 (HEK-hC5L2) cells [33] showed that TG
synthesis and glucose transport were significantly increased upon
ASP stimulation compared with non-transfected cells, resulting
in net accumulation of adipose TG stores and insulin sensitivity.
These data suggested that C5L2 was associated with hyperlip-
idemia and diabetes, which have been reported to be risk factors
of CAD. Hence, we also examined if the relationship between
the C5L2 genetic variant and CAD is modified by the
concentration of TG and glucose. There was a significant
difference between CAD patients and control subjects with
respect to the serum concentration of glucose or the frequency of
diabetes. However, it was diabetes and not the serum level of
glucose that was the independent risk factor for CAD, and this
relationship did not modify the association between C5L2
genetic variants and CAD.
In addition, although an elevated level of LDL-C in serum is an
independent risk factor for CAD, we did not find the LDL-C level
to be higher in CAD patients than in control subjects in the Han
and Uygur populations. This phenomenon may be the result from
the treatment of decreased-cholesterol drugs (e.g., simvastatin,
lovastatin) in CAD patients. Nevertheless, to evaluate the relation-
ship between LDL-C level and C5L2 genetic polymorphisms, as
an alternative method, we compared the LDL-C level between the
CC genotype and CT genotype in the control group. We found
the carriers with the T allele had higher levels of LDL-C than
those with the C allele.
In conclusion, in our sample of patients from west China, CAD
was associated with the CT genotype of 698C.T in the human
C5L2 gene. This result may broaden the knowledge of genetic
variants and disease-association studies. Undertaking genome-
wide association studies in different populations certainly merits
investigation.
Study limitation
The present study was limited by the relatively small sample
size. This may have led to weak statistical significance and wide
CIs when estimating ORs.
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Figure 2. Plasma concentrations of LDL-C in patients with coronary artery disease (CAD). (A) In the Han population, LDL-C concentrations
were significantly higher in subjects with the CT genotype than in subjects with the CC genotype. (B) In the Uygur population, LDL-C concentrations
were significantly higher in subjects with the CT genotype than in subjects with the CC genotype.
doi:10.1371/journal.pone.0020984.g002
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